Demographics
death, tumors, breast tumor, ER-positive and ER-negative
PROLIFERATIVE, TUMORS
In total, 148 (15.4%) tumors were classified as grade I, 573 (59.8%) as grade II, and 237 (24.7%) as grade III. We calculated the previously developed signature, Proliferative Index, and centered and standardized the scores to have a mean of 0 and an SD of 1. We then used the Proliferative Index to classify grade II tumors as high-risk or low-risk (In total, 139 (55.4%) of high-risk tumors had high TILs (≥10%), 62 (24.7%) had a high PD-1 expression (≥1%), and 101 (40.2%) had a high PD-L1 expression (≥1%) (Demographics of included patients*Defined as TILs ≥10% and PD-L1 and/or PD-1 ≥1%.†Defined as TILs <10% or TILs ≥10% but PD-L1 and PD-1 <1%.‡Includes both ER-positive and ER-negative tumors.§Reported as absolute frequencies rather than cumulative incidences.ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IBTR, ipsilateral breast tumor recurrence; PD-1, programmed cell death protein-1 ; PD-L1, programmed death ligand-1 ; PgR, progesterone receptor; RT, radiotherapy; TILs, tumor-infiltrating lymphocytes.In the low-risk group, high TILs were seen among 108 tumors (18.8%), high PD-1 expression among 48 (8.4%) tumors, and high PD-L1 expression among 62 (10.8%) tumors (